ImmunoCellular Therapeutics (IMUC) Tops Q4 EPS by 2c

ImmunoCellular Therapeutics (NYSE: IMUC) reported Q4 EPS of ($0.03), $0.02 better than the analyst estimate of ($0.05).

For earnings history and earnings-related data on ImmunoCellular Therapeutics (IMUC) click here.

You May Also Be Interested In

• Boyd Group Services Inc. (BGSI) Misses Q2 EPS by 19c
• Mount Logan Capital Inc. (MLCI) Reports Q2 Loss of $0.37
• Adecoagro S.A. (AGRO) Misses Q2 EPS by 63c